• 한국임상약학회지
• /
• 제26권1호
• /
• pp.84-95
• /
• 2016

Objective: Atrial fibrillation (AF) guidelines have been published in the USA and Europe. Recently, the USA and Europe have updated their guidelines, respectively. These new AF guidelines help in addressing key management issues in clinical situations. This study, therefore, systematically compared guidelines for rate and rhythm control pharmacotherapy of patients with AF between the USA (American College of Cardiology and American Heart Association, ACC/AHA) and Europe (European Society of Cardiology, ESC). Methods: This study investigated and compared American guidelines (2014) and European guidelines (2010 and 2012). Results: Generally, there are four meaningful differences between ACC/AHA and ESC guidelines. Important differences are treatment classification system, level of recommendation, drug list, and dosage. In addition, ACC/AHA described pharmacokinetic drug interactions for antiarrhythmic drugs. ESC emphasized ECG and atrioventricular nodal slowing as feature of antiarrhythmic drugs. Conclusion: This research addresses important use of anti-arrhythmic drugs and movement to accept recent recommendations in Korea. For the successful application of the guidelines, a role of pharmacists is crucial in clinical situation.

• Tuberculosis and Respiratory Diseases
• /
• 제80권3호
• /
• pp.241-246
• /
• 2017

Chronic obstructive pulmonary disease (COPD) is an ambulatory care-sensitive condition, and effective treatment of outpatients can prevent worsening of the illness and hospitalization. Current COPD guidelines provide appropriate guidance for the diagnosis and treatment of patients with COPD. In fact, it has been shown that when appropriate guidance and treatment are performed, the morbidity and mortality rates of COPD patients are reduced. However, there is a gap between the clinical guidelines and the actual clinical treatment. Therefore, the Health Insurance Review and Assessment Service (HIRA) conducted an evaluation of the adequacy of COPD diagnosis and treatment using the Claims Database of HIRA. This review provides a summary of the COPD adequacy assessment results reported by the HIRA and some brief comments on the results.

• 한국임상약학회지
• /
• 제27권4호
• /
• pp.276-283
• /
• 2017

Objective: Dyslipidemia is recognized as a prominent risk factor for cardiovascular and cerebrovascular diseases but it is manageable through therapeutic and lifestyle intervention. Interpreting the latest guidelines is essential for an application of recommendation from guidelines into clinical practice. Therefore, this study aimed to compare the most recent guidelines on dyslipidemia treatment recommendations in Korea and USA. Methods: This study analyzed and compared 2015 Korean guidelines for the management of dyslipidemia, 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and 2016 supportive guidelines from ACC. Results: A comparison was made focused on the following: target patients based on cardiovascular risk assessment, target goal, and treatment strategies including statin and non-statin therapies. Four target patient groups by risk were suggested in 2015 Korean guideline and cardiovascular risk factors were also considered for initiation of lipid lowering therapy. Titrated statin regimen was recommended by Korean guideline to reach LDL cholesterol and non-HDL cholesterol target level. In 2013 ACC/AHA guideline, four statin benefit group was introduced considering ASCVD risk and high intensity statin or intermediate intensity statin use were recommended without dose titration. 2016 update was to support non-statin therapy based on updated evidence and new consideration of ezetimibe, PCSK9-inhibitor and bile acid sequestrant was brought up. Conclusion: Guidelines are continuously updating as new and important clinical data are constantly released along with the advent of newly approved drugs for lipid disorder. This article provides resources that facilitates uptake of these recommendations into clinical practice.

• 한국융합학회논문지
• /
• 제12권5호
• /
• pp.85-91
• /
• 2021

본 연구는 치매환자에게 적합한 인지 프로그램 실무지침을 개발하는 과정에서의 효과성을 검증하는 절차를 기술한 방법론적 연구이다. 근거중심의 임상진료지침 신규개발 방법에 기초하여 국내 치매환자용 인지프로그램 실무지침 예비 권고안을 개발하였다. 이후, 효과검증을 위해 전문가 내용타당도 및 실무자 현장 적용성 검증을 수행하였다. 실무지침은 최종 4개 유형으로 구성하였으며 구성항목의 내용타당도는 0.87-1점을 나타냈다. 현장 적용성의 하위항목에서는 적절성이 3.95-4.34점, 적용가능성이 3.57-4.27점, 효과성예측이 3.84-4.22점이었다. 전문가 내용타당도 및 현장 적용성 예측 조사를 통해 본 연구에서 개발한 실무지침이 임상에 종사하는 치매 인지프로그램 관리자의 중재 계획수립과 임상 근거로 활용할 수 있음을 확인하였다. 추후 연구에서는 치매환자에게 최적의 치료적 활동을 제시하기 위한 근거중심의 실무지침 개발연구가 더욱 활성화되어야 할 것이다.

• 한국임상약학회지
• /
• 제27권2호
• /
• pp.113-118
• /
• 2017

Objective: International institutes such as Global institute for Asthma(GINA), KAAACI(Republic of Korea), NHLBI(USA), BTS(UK) and JSA(Japan) have published guidelines for asthma treatment. The aim of this study was to compare the representatives' international guidelines of pharmacotherapy for pediatric asthma. Methods: The recommendations related to pharmacotherapy for pediatric asthma were extracted from the latest representatives' international guidelines, and comprehensive comparisons were conducted. Results: Major comparison outcomes between international guidelines were evaluated as follows: classification system on severity and pediatric age group, recommendation for inhaled corticosteroid dose, recommendation for pediatric age group of theophylline in mild asthma, and recommendation for pediatric age group of tiotropium in severe asthma. Clinical trials emphasized the adverse effects of theophylline, whereas tiotropium demonstrated beneficial actions for pediatric asthma. Therefore, theophylline was recommended for older patients with persistent asthma, and tiotropium was considered to be suitable for younger patients with severe asthma according to GINA guidelines. Conclusion: These findings address the requirement to harmonize international guidelines of pharmacotherapy in pediatric asthma. In addition, the findings suggest that KAAACI needs to update its pharmacotherapy guidelines of theophylline, tiotropium and other medicines recently approved.

• 동의신경정신과학회지
• /
• 제24권spc1호
• /
• pp.47-54
• /
• 2013

Objectives : The Hwabyung Research Center of The Korean Society Of Oriental Neuropsychiatry has attempted to develop the 'Clinical Guidelines for Hwabyung'. Methods : The Hwabyung Research Center constructed a committee of experts and advisory group. Relevant literature was collected and evaluated in order to discover effective oriental psychotherapy as well as the management of Hwabyung. Results : We found some evidences that proved the effectiveness of oriental psychotherapy in the treatment of Hwabyung. The principles of management were also reviewed. Conclusions : Psychotherapy and management for Hwabyung were studies. We hope that the 'Clinical Guidelines for the Treatment of Hwabyung' is helpful for both oriental medical doctors and patients.

• 동의신경정신과학회지
• /
• 제24권spc1호
• /
• pp.3-14
• /
• 2013

Objectives : Hwabyung Research Center of The Korean Society Of Oriental Neuropsychiatry has attempted to develop 'Clinical Guidelines for the Treatment of Hwabyung' based on the clinical study on the theory of oriental medicine and phenomenological approach. The purpose of this guideline is to establish the basic clinical principles and improve the clinical convenience. Methods : Hwabyung Research Center constructed a committee of experts and advisory group. We extracted the core questions, collected the existing data and evaluated them. Simultaneously, we conducted studies on the major topics. Results : We selected and made suitable tools for the assessment and evaluation. We discovered evidences from clinical studies and developed the standard clinical principles. Conclusions : 'Clinical Guidelines for the Treatment of Hwabyung' is expected to be useful at the primary medical clinics of oriental medicine.

• 한국신뢰성학회지:신뢰성응용연구
• /
• 제2권2호
• /
• pp.99-112
• /
• 2002

Risk financing is defined as the methods applied to fund risk treatment and the financial consequences of risk. It is a major component of the transfer of risk and the retention of risk which are, in turn, parts of the risk treatment process. This study applied the general guidelines on risk financing to product liability risk. Product liability risk occurs when potential defects in the process of design, production, and distribution lead to accidents resulting in fatal, financial, and environmental loss. Risk on product liability may be financed in many different ways, each of which may be used singularly or in combination. The most popular and recommendable way suggested in the guidelines is the retention or use of reserves, transfer, credit or insurance.

• 대한영상의학회지
• /
• 제84권6호
• /
• pp.1244-1256
• /
• 2023

전립선암에서 뼈는 가장 흔한 전이병소이며, 전립선암의 질병 상태를 파악하고 치료 반응을 평가하기 위해서는 전이성 골병변의 평가가 필수적이다. 거세 저항성 전립선암은 남성호르몬을 거세 수치로 떨어뜨렸음에도 불구하고 암이 진행하는 상태를 의미하며, 이 상태에서는 원격 전이가 빈번하게 발생한다. 거세 저항성 전립선암의 치료 반응을 객관적으로 평가하기 위해 뼈스캔을 기반으로 한 Prostate Cancer Working Group 3 (이하 PCWG3) 가이드라인이 발표되었으나 실제 이를 쉽게 숙지하여 적용하기에는 어려운 점이 있다. 본 종설에서 PCWG3 가이드라인에 준한 거세 저항성 전립선암의 뼈스캔 기반 골병변 반응 평가를 위한 구체적인 영상 획득 방법 및 치료 반응 평가법을 소개하고자 한다.

• 대한한방소아과학회지
• /
• 제31권1호
• /
• pp.52-62
• /
• 2017

Objectives The purpose of this study is to review pre-existing clinical practice guidelines for autism spectrum disorders, and refer those in developing a new practice guideline. Methods A total of 9 existing clinical practice guidelines for autism spectrum disorder developed from 2010 to 2016 were searched by Google scholar and Pubmed, and were reviewed those literatures in three parts: general, diagnosis & evaluation, and intervention. Results There were no consistency in the recommendation methods of 9 clinical care guidelines (such as the method of rating and recommendation intensity for diagnosis, evaluation, and treatment). However, in the diagnosis and evaluation section, frequently used evaluation and diagnostic tools are mentioned in most clinical practice guidelines, and the types of pharmacologic and non-pharmacological treatments that are mainly recommended in treatment are equally mentioned in most clinical practice guidelines could confirm. Conclusions 1. Some guideline recommendations are graded according to each criterion. Recommendations presented in various databases were based on systematic reviews or other literatures. The most utilized database were PsycINFO, CINAHL, Cochrane. 2. DSM-5 and ICD-10 were the most common used diagnostic criteria, and DSM-IV was used as a diagnostic standard in the guideline published before 2013. The tools used for diagnosis and evaluation were also varied. However, most recommended ones were ADI-R, ADOS-G, and DISCO. 3. Treatment was largely divided into pharmacological intervention and non-pharmacological intervention. In some guideline, the interventions were divided into pediatric and adult. Most of the pharmacological interventions were not recommended due to lack of evidence, but in cases in which specific symptoms were aimed, they recommended to seek professional help. 4. In addition to interventions, each guideline referred to supportive interventions that may be helpful in the daily life of patients with ASD, which may need to be addressed in future clinical guidelines.